Filter Results:
(699)
Show Results For
- All HBS Web
(1,190)
- People (1)
- News (316)
- Research (699)
- Events (5)
- Multimedia (14)
- Faculty Publications (418)
Show Results For
- All HBS Web
(1,190)
- People (1)
- News (316)
- Research (699)
- Events (5)
- Multimedia (14)
- Faculty Publications (418)
Sort by
- 04 Feb 2014
- First Look
First Look: February 4
that investors were increasingly supporting late stage research with higher probabilities of success, while funding for riskier early stage research was drying up. Should FasterCures raise money and direct it toward early stage... View Details
Keywords: Sean Silverthlorne
- 18 Jul 2005
- Research & Ideas
Identify Emerging Market Opportunities
consumers in more-developed markets. There are few government bodies or independent publications, like Consumer Reports in the United States, that provide expert advice on the features and quality of products. Because of a lack of... View Details
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- March 2023 (Revised March 2024)
- Case
The Purdue Pharma Bankruptcy: Settling the Opioid Crisis
By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
- 01 Nov 2016
- First Look
First Look - November 1, 2016
seeks to complete its clinical trials with very little startup funding and a small staff when compared to its competitors. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/315045-PDF-ENG Harvard... View Details
Keywords: Sean Silverthorne
- 28 Apr 2009
- First Look
First Look: April 28, 2009
in the past and now influence clinical trials and participate in regulatory decision-making. Yet these developments are far from universal and... View Details
Keywords: Martha Lagace
- 27 Mar 2012
- First Look
First Look: March 27
PublicationsThe Founder's Dilemmas: Anticipating and Avoiding the Pitfalls That Can Sink a Startup Authors:Noam Wasserman Publication:The Kauffman Foundation Series on Innovation and Entrepreneurship.... View Details
Keywords: Carmen Nobel
- 18 Aug 2011
- Lessons from the Classroom
Business Plan Contest: 15 Years of Building Better Entrepreneurs
cause of blindness. In October 2009 the company entered into licensing and purchase option agreements with Alcon, which is now taking Potentia's drug candidate through Clinical 2 trials with a to-market goal... View Details
- 25 Mar 2001
- Research & Ideas
Who Wants to Be an Entrepreneur? [Part II]
initial valuations accorded such an early-stage enterprise. Cash and vision in hand, they courted senior managers from Lycos, Disney, Merrill Lynch, and elsewhere to launch the... View Details
Keywords: by John S. Rosenberg
- July 2009
- Teaching Note
The Miami Project to Cure Paralysis (TN)
By: Robert Steven Kaplan, Christopher Marquis and Ben Creo
Teaching Note for [408003]. View Details
- July 2003 (Revised February 2004)
- Background Note
M&A Legal Context: Standards Related to the Sale or Purchase of a Company
By: Carliss Y. Baldwin, Constance E. Bagley and James Quinn
Introduces students to the legal standards affecting officers and directors when selling or purchasing a company. Provides a practical understanding of the Revlon Standard, the Securities and Exchange Act of 1934, Rule 10b-5, and the legal criteria for a cause of... View Details
Keywords: Laws and Statutes; Law Enforcement; Government Legislation; Acquisition; Business Exit or Shutdown; Corporate Governance; Going Public; Courts and Trials
Baldwin, Carliss Y., Constance E. Bagley, and James Quinn. "M&A Legal Context: Standards Related to the Sale or Purchase of a Company." Harvard Business School Background Note 904-004, July 2003. (Revised February 2004.)
- 03 Nov 2015
- First Look
November 3, 2015
at facilitating communication and collaboration between practitioners and academics by introducing key vocabulary and concepts used in rigorous impact evaluation methods,... View Details
Keywords: Sean Silverthorne
- 2013
- Article
Planning Prompts as a Means of Increasing Preventive Screening Rates
By: Katherine L Milkman, John Beshears, James J. Choi, David Laibson and Brigitte C. Madrian
Keywords: Reminder Systems; Communication; Economics; Behavioral; Primary Prevention; Colonoscopy; Memory; Behavior; Health Care and Treatment; Health Testing and Trials; Communication Strategy; Health Industry
Milkman, Katherine L., John Beshears, James J. Choi, David Laibson, and Brigitte C. Madrian. "Planning Prompts as a Means of Increasing Preventive Screening Rates." Preventive Medicine 56, no. 1 (January 2013): 92–93.
- 2003
- Chapter
La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971
By: Arthur A. Daemmrich
- December 2014 (Revised August 2015)
- Case
Improving Melanoma Screening: MELA Sciences
By: Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols
MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and... View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
providing incentives and protecting proprietary information as needed—then leveraging the latest in artificial intelligence and machine learning through entities such as GNS Healthcare View Details
- March 30, 2020
- Article
Why Is the U.S. Behind on Coronavirus Testing?
By: Stefan Thomke
Coronavirus testing is needed to address the uncertainty in making decisions about patient treatment, resource allocation, policy, and so much more. Answers to questions such as “When should we relax social distancing measures—and for whom?” or “How many ventilators... View Details
Keywords: Testing; Coronavirus; Culture; Trump; Data; Experiments; Health Pandemics; Health Testing and Trials; Government and Politics; United States
Thomke, Stefan. "Why Is the U.S. Behind on Coronavirus Testing?" Harvard Business Review Digital Articles (March 30, 2020).
- 02 Nov 2020
- What Do You Think?
Is Antitrust Just a Quaint Notion in the Digital Age?
information age in which the “product” is readily shared, can’t be hoarded, and is a result of a network, how will it be feasible for regulators and courts to prohibit business... View Details
Keywords: by James Heskett; Retail; Technology; Telecommunications; Communications; Consumer Products; Service
- February 2020
- Supplement
Theranos: Who Has Blood on Their Hands? (B)
By: Nien-he Hsieh, Christina R. Wing and John Masko
This supplemental case tracks the results of the Colman and Taubman-Dye class action suit against Theranos as well as Theranos’ other legal challenges and chronicles the final demise of the company in 2019. View Details
Keywords: Health Testing and Trials; Corporate Accountability; Organizational Culture; Misleading and Fraudulent Advertising; Crime and Corruption; Entrepreneurship; Lawsuits and Litigation; Business Exit or Shutdown; Medical Devices and Supplies Industry; California; United States
Hsieh, Nien-he, Christina R. Wing, and John Masko. "Theranos: Who Has Blood on Their Hands? (B)." Harvard Business School Supplement 320-091, February 2020.
- 18 Jun 2014
- Research & Ideas
Leading Innovation is the Art of Creating ‘Collective Genius’
conflict, and trial and error to advantage. At Pixar, for example, the company was caught up short in 2008 in a clash over production schedules for the movie Up View Details
Keywords: by Kim Girard